Don Rindell has more than 25 years of senior executive experience in the life sciences industry. He has held executive roles in global corporate development, business development and device/technology strategy for several US and European pharmaceutical and medical device companies.
Mr. Rindell is currently Managing Director of Camino International, LLC, a consulting practice for Business and Product Development for drug delivery therapeutics and medical devices. He most recently served as Senior Director of Corporate Development at Amylin Pharmaceuticals, which was purchased by Bristol Myers Squibb. At Amylin, he led a number of key global transactions with partners including Shionogi Pharmaceuticals, BIOCON, Takeda Pharmaceuticals and selected device delivery companies. He also provided senior management leadership to the Amylin Drug Delivery/Device Team. He has previously held senior executive positions at CardioNet, Advanced Tissues Sciences, Braun/Thermoscan, Hybritech, and Syntex.
Mr. Rindell is a member of the Board of Directors of publicly traded TearLab (NASDAQ: TEAR), and advisor to two other medical device companies.
Mr. Rindell received his B.A. degree in Economics from the College of Wooster and an M.B.A. from Pepperdine University Graduate School of Business.